Voyager presents six-month data for Alzheimer’s gene therapy

Voyager presents six-month data for Alzheimer’s gene therapy

Gold slides as U.S.-Iran conflict lifts oil, hawkish Fed bets grow LEXINGTON, Mass. - Voyager Therapeutics Inc. (NASDAQ:VYGR) presented six-month toxicology data for VY1706, an investigational gene therapy targeting tau protein for Alzheimer’s disease, at the Alzheimer’s Association International Conference in London. The data, presented in a late-breaking poster on Monday, showed VY1706 reduced tau protein by up to 75% in key brain regions of non-human primates following a single intravenous dose over a six-month period, according to a press release statement. The company reported the therapy was well tolerated with no adverse findings in the central nervous system, dorsal root ganglia, and peripheral organs including the liver at the highest dose tested.

Trading at $3.44 with a market cap of $208 million, Voyager appears undervalued according to InvestingPro analysis, with analyst price targets ranging from $8 to $25. The company maintains a strong current ratio of 8.42, though InvestingPro Tips note it is quickly burning through cash—typical for clinical-stage biotechnology firms. Voyager received U.S. Food and Drug Administration Investigational New Drug clearance for VY1706 in June.

The company expects to begin dosing adults with early Alzheimer’s disease in the second half of this year. VY1706 uses a vectorized siRNA to target MAPT mRNA, aiming to decrease levels of both intracellular and extracellular tau in the brain. The therapy is encapsulated in Voyager’s TRACER AAV capsid, which uses ALPL, a brain vasculature endothelial receptor, to cross the blood-brain barrier following intravenous administration.

The six-month study demonstrated dose-dependent delivery to the central nervous system with up to 75% reduction of MAPT mRNA and tau protein in Alzheimer’s disease-relevant brain regions. The company previously presented three-month data for VY1706 at the American Society of Gene & Cell Therapy’s annual meeting in May 2026. Voyager is a biotechnology company focused on developing gene therapies for neurological diseases.

The company maintains partnerships with Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, and Neurocrine Biosciences Inc. In other recent news, Voyager Therapeutics Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for VY1706, an experimental gene therapy targeting tau protein for Alzheimer’s disease treatment. This clearance allows Voyager to begin a clinical trial in adults with early Alzheimer’s disease, with dosing anticipated to start in the second half of 2026.

The trial will be a multi-site, open-label, dose-escalation study, administering a single intravenous dose of VY1706 to participants. Additionally, Voyager presented preclinical data at the American Society of Gene & Cell Therapy’s annual meeting, showing that VY1706 was well tolerated in non-human primates and effectively reduced tau protein levels. The company also shared plans to present further preclinical data at the upcoming Alzheimer’s Association International Conference in London.

H.C. Wainwright reiterated a Buy rating for Voyager Therapeutics, citing progress in their VY1706 program. The firm highlighted the completion of a key toxicology study that supports the IND filing, with a first-in-human study expected to start in the second half of 2026.